trial · primary record
barzolvolimab
Chronic Spontaneous Urticaria
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1370 |
| Primary completion | 2028-09 |
| Primary endpoint | Time to disease worsening or treatment failure through Week 52 based on the occurrence of UAS7 (Urticaria Activity Score) of 16 or greater. |
| Registry ID | NCT07256392 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:09.268Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07256392
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- barzolvolimab · compound